Related references
Note: Only part of the references are listed.
Article
Microbiology
Roanne Keeton et al.
Summary: The study shows that vaccination with Ad26.COV2.S after infection can significantly enhance protection against COVID-19, especially against different virus variants. In addition, the vaccine also induces robust CD4 and CD8 T cell responses, regardless of prior infection.
CELL HOST & MICROBE
(2021)
Article
Immunology
Lydia Riepler et al.
Summary: Neutralizing antibodies are crucial for protection against viruses like SARS-CoV-2. This study compared four different assays for detecting these antibodies and found that they were all robust and yielded comparable results, indicating their reliability.
Article
Medicine, General & Internal
Kathryn E. Stephenson et al.
Summary: The study evaluated the immunogenicity of the Ad26.COV2.S vaccine in human participants, showing rapid induction of spike-specific humoral and cellular immune responses. Various antibody subclasses, Fc receptor binding properties, and antiviral functions were induced, along with CD4+ and CD8+ T-cell responses.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Houriiyah Tegally et al.
Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.
Article
Biochemistry & Molecular Biology
Constantinos Kurt Wibmer et al.
Summary: The SARS-CoV-2 virus in the B.1.351 variant discovered in South Africa can evade neutralization by most antibodies when expressed, but does not affect binding by convalescent plasma. This suggests the potential for reinfection with antigenically distinct variants and predicts reduced efficacy of spike-based vaccines.
Article
Medicine, General & Internal
Juanjie Tang et al.
Summary: This study highlights the differences in antibody affinity maturation between individuals with prior COVID-19 infection and naive individuals post mRNA vaccination. Higher neutralizing antibodies were observed in convalescent individuals compared to naive individuals, along with differences in antibody binding and affinity. Additionally, males showed significantly higher antibody affinity against SARS-CoV-2 prefusion spike compared to females among the naive participants. Further research is needed to determine the role of antibody affinity in protection against SARS-CoV-2 and its variants.
Article
Medicine, General & Internal
Ezgi Hacisuleyman et al.
Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Frauke Muecksch et al.
Summary: This study examined the development of antibodies following infection with the coronavirus, finding that evolved antibodies had increased affinity and neutralization potency, altered mutational pathways for viral resistance, and restricted neutralization escape options. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying populations of the virus and other pandemic threat coronaviruses.
Letter
Medicine, General & Internal
Dan H. Barouch et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Immunology
Yuying Lu et al.
Summary: The COVID-19 pandemic has caused a global health emergency with tremendous efforts put into controlling it. Neutralizing antibodies are of interest to researchers for their ability to protect cells and potentially be used in vaccines and patient treatment. Various neutralization assays are being developed to quantify these antibodies and explore their relationship with disease severity and potential for reinfection in patients.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Microbiology
Jia Wei et al.
Summary: A longitudinal study on 45,965 adults in the UK revealed that older individuals, especially those aged >60 years, had lower antibody levels after a single dose of ChAdOx1 or BNT162b2 COVID-19 vaccines. Prioritizing vaccine allocation for those not previously infected and older individuals for the second dose is recommended based on the findings. Further data is needed to fully understand the relationship between quantitative antibody responses and vaccine-mediated protection.
NATURE MICROBIOLOGY
(2021)
Article
Immunology
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Tomer Zohar et al.
Review
Immunology
David S. Khoury et al.
NATURE REVIEWS IMMUNOLOGY
(2020)